Company intelligence / Profile preview

Ukko Energy

Palo Alto, California, USAukko.energy ↗

Ownership: Private
Employees: ~51
Development stage: Other

Overview

Ukko is developing engineered proteins to treat food allergies and sensitivities. Its lead program targets peanut allergy with a novel therapeutic designed to reprogram immune tolerance without triggering allergic reactions. The company is also developing improved gluten products suitable for people with celiac disease or gluten sensitivity. As of early 2021–2024, its peanut allergy program was preparing to enter clinical trials.

Therapeutic areas: GastroenterologyImmunology
Modalities: ProteinBiologic
Industry: Biotech

Partnerships

Leaps by Bayer

Beyond the preview

Go deeper on Ukko Energy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ukko Energy.

Explore the full profile